Vanda Pharmaceuticals Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Accelerated filer
State of Incorporation DE
Business Address 2200 PENNSYLVANIA AVE NW, WASHINGTON, DC, 20037
Mailing Address 2200 PENNSYLVANIA AVE NW, WASHINGTON, DC, 20037
Phone 202-734-3400
Fiscal Year End 1231
EIN 030491827
Financial Overview
FY2025 FY
$216.10M
Revenue
$656.20M
Total Assets
$102.32M
Cash & Equivalents
$0.04
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | February 12, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | February 12, 2026 | View on SEC |
| 8-K Current report of material events | February 11, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 21, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | January 9, 2026 | View on SEC |
| 8-K Current report of material events | January 8, 2026 | View on SEC |
| 8-K Current report of material events | December 31, 2025 | View on SEC |
| 8-K Current report of material events | December 4, 2025 | View on SEC |
| 8-K Current report of material events | November 28, 2025 | View on SEC |
| 10-Q Quarterly financial report | October 30, 2025 | View on SEC |
Annual Reports
10-K February 12, 2026
- Nereus (Tradipitant), a key pipeline asset, is nearing FDA approval with a "Regulatory approval milestone" anticipated by the end of 2025.
- Strategic acquisition of PONVORY for $50 million in late 2023 diversified the portfolio, contributing an initial $20 million to 2025 revenue.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.